The United Kingdom and the United States have secured a key commercial pact that will ensure no tariffs on British medicine products going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise funding on drugs through the public health system. This commitment guarantees that tariffs on these vital exports will remain at zero for a period of 36 months.
This development is in response to recent threats to dramatically increase import taxes on branded drug products, with increases discussed up to 100%.
"This arrangement with the United Kingdom reinforces the worldwide climate for innovative medicines and brings much-needed fairness to American-British medicine commerce," a statement noted.
Trade Significance
Medicines constitute one of the the United Kingdom's biggest exports to the United States, which is clearly the primary buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period to the end of last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that period.
"This agreement secures work, boosts investment and facilitates the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The pact includes several key changes from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. Last year, repayments exceeded twenty percent.
Broader Context
The pact takes place against a protracted tension between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were heightened by arguments that US customers were paying significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while substantial expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the past decade.
